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The Ciba Foundation
The Ciba Foundation was opened in 1949 to promote international cooperation in medical and chemical research. It owes its existence to the generosity of CIBA Ltd, Bade, who, recognizing the obstacles to scientific communication created by war, man's natural secretiveness, disciplinary divisions, academic prejudices, distance, and differences of language, decided to set up a philanthropic institution whose aim would be to overcome such barriers. London was chosen as its site for reasons dictated by the special advantages of English charitable trust law (ensuring the independence of its actions), as well as those of language and geography.
The Foundation's house at 41 Portland Place, London, has become well known to workers in many fields of science. Every year the Foundation organizes six to ten three-day symposia and three to four shorter study groups, all of which are published in book form. Many other scientific meetings are held, organized either by the Foundation or by other groups in need of a meeting place. Accommodation is also provided for scientists visiting London, whether or not they are attending a meeting in the house.
The Foundation's many activities are controlled by a small group of distinguished trustees. Within the general framework of biological science, interpreted in its broadest sense, these activities are well summed up by the motto of the Ciba Foundation:
Consocient Gentes-let the peoples come together.
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CHAIRMAN'S OPENING REMARKS DR F. H. C. CRICK
THE programme of our meeting has a logical structure, starting off with the pharmacological properties of receptors, going on to the structure of active sites in enzymes, then to conformational changes-that is really to proteins and what they can do-and finally to the isolation and characterization of receptors themselves. There is general agreement now, from what we know of molecular biology as a whole, that receptors are likely to be proteins, or at least that proteins are a very important part of receptors. There have also been developments, especially in the last five to seven years, in our knowledge of protein structure. The basic idea of the symposium is to try to bring these two aspects together. This is somewhat of an experiment in that we still don't know fully what proteins can't do, though we do know fairly well a number of things they can do and we have a shrewd idea ofthe sort ofway they do them. But we still can't predict, for example, how they fold up. These are limitations in our knowledge which we hope will be removed in the next five or ten years. The other general remark I will make is that people here come from very different disciplines. I would therefore appeal to people on both the pharmacological side and the protein side not just to talk to the people who already know the field but to the opposite side. My only usefulness as Chairman is that I have got to the stage where I hardly know about either side. Consequently up to a point I can ask the silly questions, but I hope that everyone else will do so too if a speaker is usingjargon about his own subject. THE pharmacological knowledge which has led to, and to some extent defined, the idea of the drug receptor can be arranged in three parts, concerned with (a) structure-action relationships and chemical specificity of drugs, (b) sites ofaction and the selectivity in the body ofresponses to drugs, and (c) the quantitative functional relationships demonstrable in drug action.
STRUCTURE-ACTION RELATIONSHIPS AND CHEMICAL SPECIFICITY
It has long been known that particular chemical structures produce particular actions. Just over IOO years ago Crum Brown and Fraser (I 869) showed that the quaternizing with methyl iodide of a series of amines (such as morphine, atropine, strychnine, nicotine) removed their characteristic actions and produced compounds with a single action-curare-like. Their generalization, which by hindsight we can see as a pointer to the transmitter function of acetylcholine at the neuromuscular junction, is still one of the best; and it prompted their proposal of a programme of a "calculus of finite variations" for defining the functional relation between chemical constitution and physiological action. This programme, though it often leads to a quagmire, has had its successes, including the recognition of families of drugs built around and approaching in structure some natural transmitter or hormone such as acetylcholine (Table I ) or noradrenaline; other groups, such as local anaesthetics, the opiates, phenothiazines, barbiturates, thiazide diuretics, veratrine derivatives and cardiac glycosides, must reflect properties of biochemical molecules or structures still unidentified.
These studies have, of course, produced ad hoc rules, useful in the develop ment of new drugs, but clearly limited: the pharmaceutical industry produces only one clinically successful drug for every 2000-5000 investigated, and despite many efforts there is a lack of good antagonists, for example to histamine (on gastric secretion) or to gastrin, bradykinin or the proposed model-usually as anionic sites, dipoles, sites for hydrogen bonding, crevices, planar aromatic surfaces, or hydrophobic areas laid out in spatially critical array. But when these models are compared with known macromolecular structures, our ignorance of the scaffolding underlying the postulated elements becomes obvious; and the clues obtained from those elements as to the underlying structure seem depressingly slight. The task is like that of reconstructing a fossil animal given only an upper and lower molar.
P H A R M A C O L O G I C A L PROPERTIES OF RECEPTORS
5
These structural studies, in conjunction with functional estimates of potency and affinity, have also led to attempts to partition the free energy of binding ofa molecule into coniponents attributable to different elements. The original hope (Barlow, Scott and Stephenson, 1963) 
FIG. a. Hypothetical model of the receptor for morphine-like analgesics.
From Beckett (1959) .
has not been fulfilled (Burgen, 1965 ;  Abramson et a!., 1969) ; and Burgen has an interesting analysis indicating inter alia that, whde with acetylcholine the cationic head is about 0.3 3 nm (3 * 3 A) away from the anionic site, for an antagonist such as atropine the binding forces on the rest of the molecule pull the nitrogenous head further away (0.5 nm), reducing the ionic component. It is just possible that such studies could, with more effort and with an analysis of the interactions, produce a useful and specific indication of the nature ofa binding group in the receptor : but it seems more likely that this information will serve as a useful cross-check on a proposed structure arrived at on other grounds. Lonsdale, Milledge and Pant (1965) concluded from a study of the crystal structure of methonium compounds that their pharmacological action depended primarily on the binding of the aliphatic chain, with the quaternary nitrogen atoms playing little part save as carriers of methyl groups. But so great is the difference in pharmacological properties between decaor hexamethonium on the one hand and decyl-or hexyltrimethylammonium on the other, that my doubts (nowadays heretical) about the application of knowledge about crystals to the properties of molecules in dilute solution were revived. Such chemical and physicochemical studies, therefore, have not proved to be a definite guide to receptor structure; and one ultimately becomes as disenchanted with them, in this respect, as with the parallel process in radiobiology of trying to identi6 the primary events of radiation damage simply by varying the physical parameters of the radiation. Nevertheless, there are certain pointers to which attention should be drawn. First, a number of drugs, particularly trypanocidal diamidines, ganglionic and neuromuscular blocking agents, antiseptics (chlorhexidine and dequalinium) and histamine liberators (MacIntosh and Paton, 1g4g), are "bifunctional" in the sense that they are all molecules with similar nitrogenous terminal groups separated by a more or less elaborate hydrocarbon skeleton, in which both cationic heads are required for potency. In the methonium series (Fig. 3) , which is chemically rather dull, there is a particularly striking change of potency and type of action with varying length of methylene chain between two identical cationic heads. Secondly, it is noteworthy that some active drugs are chemically very simple, e.g. pempidine, tetramethylammonium and tetraethylammonium, and piperazine, as well as the methonium compounds just mentioned. Thirdly, one must mention stereoisomerism. Pasteur in I 886 attributed the sweetness of D-asparagine compared to the L-isomer to the presence of an optically active substance in the nervous mechanism of taste. Cushny (1926) drew particular attention to this aspect, remarking about the isomers of hyoscyamine in a charming and relevant phrase that I ' . . . there can hardly be any question that the action is on a single receptor which embraces both isomers though with unequal warmth.'' As a result ofhis work, some receptors at least had to be three-dimensional arrays (or two-dimensional approached from one side only). Pfeiffer (1956) has proposed an interesting rule (Fig. 4) that the potency ratio between isomers increases as absolute potency increases-a reasonable idea if one supposes that to achieve potency additional binding forces are required, which may well prove asymmetric. Finally, one must mention the high potencies which can be achieved. Most worthwhile drugs are effective at I O -~ M, some at I O -~ or 10-l~ M or less. This fact alone implies some special mechanism for recognition and transduction. -- 
SITES OF ACTION AND SELECTIVITY OF RESPONSES
Therapeutics rests on the selectivity of drug action. But Langley's (1907)
observation that nicotine produced a focal contracture had to appear before it was possible to postulate a "receptive substance" aspart of a cell surface, as distinct from supposing that whole cells respond in this or that way. One can point, in addition, to quite striking selectivities among antihistamines, atropine-like substances, the methonium compounds, neuromuscular blocking agents, opiates, or histamine liberators, where a drug active primarily on one cell type may need to be given in a hundred or a thousand times higher concentration to affect other cells.
The significance of this selectivity is emphasized by comparison with the general anaesthetics (Fig. 5) . These affect most systems tested at concentrations varying by less than a factor often (usually much less). Specificity of chemical structure is well known to be equally slight; indeed solubility properties appear to be the main determinant of anaesthetic action, and anaesthetics varying in potency over a range of 5000 or more (from chloroform to nitrogen) become virtually equipotent if potency is multiplied by solubility in a fatty phase with a solubility parameter of around 9 (Fig. 6) . The general pattern of drug specificity and selectivity, i.e. the range of structures that one drug will affect and the range of drugs to which one The relationship between alcohol chain length and the concentration required for 50 per cent depression of gut contractility ( x ), paramecium mobility (0), lung oxygen consumption (+), and lung histamine release (a). The curves have been smoothed out for clarity. From Rang (1960) .
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structure will respond, seems roughly comparable to the analogous pattern for enzyme substrates and inhibitors. One difference, perhaps, is in the number of receptor types for which genetic specification might be required. In systems where it is reasonably sure that thedrug is neither a substrate for an enzyme nor competing with a substrate, and for which both agonists, antagonists, and the appropriate functional relationships exist, I can name only 14 receptor types : three for acetylcholine, two for catecholamines (disregarding refinements), two for hydroxytryptamine, two for histamine, one for morphine, one each for y-aminobutyric acid (GABA) and glycine, and two for pituitary peptides. From differential assays made possible by choice of tissue and by the desensitization methods used before specific antagonists are found, I would add another four-for bradykinin, substance P, prostaglandins and slow-reacting substances. Less certain are the receptor requirements implied for veratrine, phenylbiguanide and tetraethylammonium; for tetrodotoxin and other local anaesthetics; for picrotoxin, metrazol, the hydantoins, troxidone and ethosuximide and phenothiazines ; for digitalis, endogenous pyrogen, histamine liberators, aspirin, and steroid hormones. There are, too, the specific transport mechanisms, handling catecholamines, choline, aromatic acids, sodium and potassium, amino acids and glucose.
But it would be difficult to count more than 50 receptors which can be reasonably well distinguished. Although we need many more than just a handful of mechanisms, the number required is one or two orders of magnitude smaller, I think, than the number of enzymes which can be distinguished in animal tissues, and it is well within the capacity of the genes.
FUNCTIONAL STUDIES
It was not until the third set of experiments developed-that is quantitative work on agonists, antagonists and their interactions-drawing, of course, for their tools on the chemical and pharmacological data already Sir Henry Dale: "It is a mere statement of fact to say that the action of adrenaline picks out certain effector cells and leaves others unaffected; it is a simple deduction that the affected cells have a special affinity of some kind for adrenaline; but I doubt whether the attribution to such cells of 'adrenaline-receptors' does much more than restate this deduction in another form" (p. 320).
Dr H. R. Ing: "Sir Henry Dale criticized the receptor theory on the ground that it added nothing to our knowledge, but was only an alternative way of describing the well-established pharmacological facts. The theory is not meant to be other than an alternative method of describing the known facts, which, however, is thought to have the additional advantages of suggesting new approaches to the problems and of providing a much-needed intellectual link between the diverse concepts ofchemical structure and pharmacological action" (p. 380). k,, k,, k, are rate constants; KB(=k,/k,) and K,, dissociation constants for E and I respectively.
p denotes "occupancy", i.e. the proportion of the receptors occupied by molecules of E ; pe, the equilibrium occupancy.
D R denotes dose ratio, the ratio by which the dose of stimulant must be increased to produce, in the presence of inhibitor, some standard response.
A denotes the rate of association of drug molecules with the receptor. The diagrams show equation (3) with arithmetical scale for x , and equations (3) and ( 5 ) with logarithmic scale for x, allowing the dose ratio to appear as a lateral shift. straightforward to determine KE for a competitive antagonist at any convenient dose ratios. As Schild (1961) pointed out, the KE (equivalent to the antilogarithm of the negative of his PA, [Schild, 1947, 19491 , if competitive equilibrium has been reached) is rather constant for a given agonist/antagonist combination, even on preparations as different as chick amnion, perfused lung and small intestine. The model, in addition, Dose-response curvesfor ugonists But the position for agonist dose-response curves is much more obscure.
Clark had already collected instances for which the dose-response curve could only be fitted if n # I ; and it is in fact quite easy, by changing the recording system, to alter theshape quite widely. But on present knowledge the shape of the curve neither endorses the Langmuir model (when it happens to fit it) nor refutes it (when it does not fit it). In the sequence of unknown events between the drug-receptor interaction and the final response (involving, for the common type of test, conductance change, membrane potential change, ionic movements and activation of contractile mechanism), all that one is entitled to expect is a smooth response curve which must have a maximum, since the capacities of tissues to respond are not unlimited. There is, too, the question of "backlash" in the system, represented by Hill (1910) as "M", the least amount of drug-receptor complex required for any response to be seen, and as "a", a correction to the resting membrane potential, in Higman, Podleski and Bartels' experiments (1963) on the electroplax. This can arise from lever loading in mechanical systems (cf. Paton, 1961); for other methods of recording, sites of loss of drug or background chemoceptive activity could be responsible. With kinetic studies, diffusive delays are a problem, and with contractile responses the force-velocity curve of the muscle may affect the results profoundly. For such reasons, one needs to push the recording of the response back as close as possible to the drug-receptor interaction; it is not at allclearwhether, for instance, the recording even of drug-induced changes in membrane conductance is as near to the drug-receptor complex as is, say, the rate of substrate breakdown to the substrate-enzyme complex. It is remotely possible, since Langmuir relationships in series yield an overall Langmuir relation, that the rather good fit which can be obtained of a dose-response curve to such a function is not fortuitous. For the time being, however, fortuitousness must be assumed. But there is, in my mind, a deeper reason for doubt about the shape of a dose-response curve-namely desensitization. With smooth muscle at least, any chemoceptive activation is followed by a period of reduced sensitivity (Fig. 10) . It is greater the larger the dose and the longer the exposure.
Since the reduction is also greater the sooner one tests for it after the conditioning exposure, I think one must suppose it is developing during the conditioning period. Consequently, one must consider a dose-response curve as permeated with a steadily increasing, and usually unknown, degree of desensitization as the dose increases; indeed one can construct a variety of dose-response curves according to how one obtains them. A practical consequence is that, since the preparation is sensitive to its past history (or at least the last 10 to 15 minutes ofit), it is best to work as far as possible with equally spaced and equal-sized responses.
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